
Hot trades in Hong Kong stocks (7.29)|Xiaomi's stock price hits a 1-month low, while innovative drug concepts buck the trend and rise!

Hot Trading Industry Trends and Related Hong Kong Stocks
CRO / Innovative Drug Sector Continues Strong Performance
$WUXI APPTEC(02359.HK) reported doubled interim profits, igniting the pharmaceutical outsourcing sector. Besides the positive interim results from WuXi AppTec, other pharmaceutical firms' mid-year performance forecasts indicate a steady recovery trend for CRO and CDMO companies.
Institutions suggest the pharmaceutical industry has reached a turning point. Zhongtai Securities pointed out in its latest research report that global demand is improving, and financing expectations are optimistic. Domestic reserve requirement ratio cuts, interest rate reductions, the completion of large BD deals for innovative drugs, and improved financing conditions are expected to boost domestic investment and CRO demand.
CRO Concept Stocks: $WUXI APPTEC(02359.HK), $WUXI BIO(02269.HK), $TIGERMED(03347.HK), $JOINN(06127.HK), $PHARMARON(03759.HK);
Innovative Drug Concept Stocks: $HENGRUI PHARMA(01276.HK), $BEONE MEDICINES(06160.HK), $HANSOH PHARMA(03692.HK), $INNOVENT BIO(01801.HK), $SINO BIOPHARM(01177.HK), $AKESO(09926.HK), $CSPC PHARMA(01093.HK), $3SBIO(01530.HK), $ZAI LAB(09688.HK), $SIMCERE PHARMA(02096.HK);
Biotech B-Shares: $SKB BIO-B(06990.HK), $ASCENTAGE-B(06855.HK), $EVEREST MED(01952.HK), $KEYMED BIO-B(02162.HK), $LEPU BIO-B(02157.HK), $CARSGEN-B(02171.HK)
Today's Hong Kong Tech Stocks Declined: $XIAOMI-W(01810.HK), $TENCENT(00700.HK), $BILIBILI-W(09626.HK), $KUAISHOU-W(01024.HK), $NTES-S(09999.HK), $BABA-W(09988.HK), $MEITUAN(03690.HK)
Among them, $XIAOMI-W(01810.HK) fell for three consecutive days, hitting a one-month low.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
